<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="cam470546" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40007233</article-id><article-id pub-id-type="pmc">PMC11862098</article-id><article-id pub-id-type="doi">10.1002/cam4.70546</article-id><article-id pub-id-type="publisher-id">CAM470546</article-id><article-id pub-id-type="other">CAM4-2024-06-3744.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Prognostic Impact of Oncogenic Fibroblast Growth Factor Receptor Alterations in Patients With Advanced Solid Tumors in a Real&#x02010;World Setting</article-title></title-group><contrib-group><contrib id="cam470546-cr-0001" contrib-type="author" corresp="yes"><name><surname>Demirdjian</surname><given-names>Levon</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1854-3658</contrib-id><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>ldemirdj@its.jnj.com</email></address></contrib><contrib id="cam470546-cr-0002" contrib-type="author"><name><surname>Triantos</surname><given-names>Spyros</given-names></name><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470546-cr-0003" contrib-type="author"><name><surname>Standish</surname><given-names>Kristopher</given-names></name><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470546-cr-0004" contrib-type="author"><name><surname>Thomas</surname><given-names>Shibu</given-names></name><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470546-cr-0005" contrib-type="author"><name><surname>Xia</surname><given-names>Qi</given-names></name><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470546-cr-0006" contrib-type="author"><name><surname>Zhang</surname><given-names>Jiarui</given-names></name><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470546-cr-0007" contrib-type="author"><name><surname>Greshock</surname><given-names>Joel</given-names></name><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="cam470546-cr-0008" contrib-type="author"><name><surname>Paone</surname><given-names>Julie</given-names></name><xref rid="cam470546-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470546-cr-0009" contrib-type="author"><name><surname>Sheridan</surname><given-names>Paige</given-names></name><xref rid="cam470546-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="cam470546-cr-0010" contrib-type="author"><name><surname>Pant</surname><given-names>Shubham</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9281-480X</contrib-id><xref rid="cam470546-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="cam470546-cr-0011" contrib-type="author"><name><surname>Massard</surname><given-names>Christophe</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5505-0564</contrib-id><xref rid="cam470546-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cam470546-cr-0012" contrib-type="author"><name><surname>Reardon</surname><given-names>David A.</given-names></name><xref rid="cam470546-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="cam470546-cr-0013" contrib-type="author"><name><surname>Loriot</surname><given-names>Yohann</given-names></name><xref rid="cam470546-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="cam470546-cr-0014" contrib-type="author"><name><surname>Schuler</surname><given-names>Martin</given-names></name><xref rid="cam470546-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="cam470546-cr-0015" contrib-type="author"><name><surname>Sweiti</surname><given-names>Hussein</given-names></name><xref rid="cam470546-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cam470546-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Janssen Research &#x00026; Development</institution>
<city>Spring House</city>
<named-content content-type="country-part">Pennsylvania</named-content>
<country country="US">USA</country>
</aff><aff id="cam470546-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Aetion</institution>
<city>New York</city>
<named-content content-type="country-part">New York</named-content>
<country country="US">USA</country>
</aff><aff id="cam470546-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>The University of Texas, MD Anderson Cancer Center</institution>
<city>Houston</city>
<named-content content-type="country-part">Texas</named-content>
<country country="US">USA</country>
</aff><aff id="cam470546-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Gustave Roussy</named-content>
<institution>Universit&#x000e9; Paris Saclay</institution>
<city>Villejuif</city>
<country country="FR">France</country>
</aff><aff id="cam470546-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Dana&#x02010;Farber Cancer Institute and Harvard Medical School</institution>
<city>Boston</city>
<named-content content-type="country-part">Massachusetts</named-content>
<country country="US">USA</country>
</aff><aff id="cam470546-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">West German Cancer Center</named-content>
<institution>University Hospital Essen</institution>
<city>Essen</city>
<country country="DE">Germany</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Levon Demirdjian (<email>ldemirdj@its.jnj.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>14</volume><issue seq="290">4</issue><issue-id pub-id-type="doi">10.1002/cam4.v14.4</issue-id><elocation-id>e70546</elocation-id><history>
<date date-type="rev-recd"><day>06</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>27</day><month>6</month><year>2024</year></date>
<date date-type="accepted"><day>15</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 Published by John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 Johnson and Johnson, Aetion and The Author(s). <italic toggle="yes">Cancer Medicine</italic> published by John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:CAM4-14-e70546.pdf"/><abstract><title>ABSTRACT</title><sec id="cam470546-sec-0001"><title>Background</title><p>Somatic <italic toggle="no">FGFR</italic> gene alterations (<italic toggle="no">FGFRalt</italic>) may act as oncogenic drivers across several cancers. The prognostic impact of <italic toggle="no">FGFRalt</italic> in solid tumors is not fully understood. We assessed the prognostic impact of <italic toggle="no">FGFRalt</italic> on overall survival (OS) in a tumor&#x02010;agnostic real&#x02010;world cohort of patients with advanced solid tumors.</p></sec><sec id="cam470546-sec-0002"><title>Methods</title><p>This was a retrospective, observational, comparative cohort analysis that used data from a nationwide de&#x02010;identified clinico&#x02010;genomic database. Patients were included if they had advanced/metastatic disease, were aged&#x02009;&#x02265;&#x02009;18&#x02009;years at the time of diagnosis, had evidence of genomic testing for <italic toggle="no">FGFRalt</italic>, and had initiated first&#x02010;line systemic therapy for their cancer. Patients without <italic toggle="no">FGFR</italic> alterations (<italic toggle="no">FGFRneg</italic>) were matched 3:1 with patients with <italic toggle="no">FGFRalt</italic> using a combination of exact matching on tumor type and Mahalanobis&#x02010;distance matching on selected clinical confounders. The primary endpoint was OS from time of initiation of first&#x02010;line therapy in patients with <italic toggle="no">FGFRalt</italic> versus <italic toggle="no">FGFRneg</italic>. To further mitigate bias, delayed entry models and covariate&#x02010;adjusted stratified Cox models were implemented.</p></sec><sec id="cam470546-sec-0003"><title>Results</title><p>The final cohort included 1012 patients (253 <italic toggle="no">FGFRalt</italic>, 759 <italic toggle="no">FGFRneg</italic>), across 30 tumor types. There were no significant differences in real&#x02010;world OS from first&#x02010;line therapy between <italic toggle="no">FGFRalt</italic> and <italic toggle="no">FGFRneg</italic> groups (hazard ratio 0.97; <italic toggle="no">p</italic>&#x02009;=&#x02009;0.78). Median OS from initiation of first&#x02010;line therapy was 1.13&#x02009;years (95% confidence interval [CI] 0.92&#x02013;1.52) and 1.01&#x02009;years (0.89&#x02013;1.15) for the <italic toggle="no">FGFRalt</italic> and <italic toggle="no">FGFRneg</italic> groups, respectively.</p></sec><sec id="cam470546-sec-0004"><title>Conclusions</title><p>In this matched&#x02010;cohort real&#x02010;world analysis, presence of <italic toggle="no">FGFRalt</italic> had no impact on the prognosis of patients with advanced solid tumors receiving standard&#x02010;of&#x02010;care treatment.</p></sec></abstract><abstract abstract-type="graphical"><p>In this statistically powered and matched&#x02010;cohort real&#x02010;world analysis, there was no statistically significant difference in real&#x02010;world overall survival between matched patients with <italic toggle="yes">FGFR</italic>&#x02010;altered or <italic toggle="yes">FGFR</italic>&#x02010;negative advanced solid tumors, with a median overall survival of ~1&#x02009;year in both groups. These results highlight the poor prognosis of patients with advanced solid tumors harboring <italic toggle="yes">FGFR</italic> alterations and the need for novel, targeted therapies.<boxed-text position="anchor" content-type="graphic" id="cam470546-blkfxd-0001"><graphic xlink:href="CAM4-14-e70546-g002.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam470546-kwd-0001">erdafitinib</kwd><kwd id="cam470546-kwd-0002">fibroblast growth factor inhibitor</kwd><kwd id="cam470546-kwd-0003">real&#x02010;world evidence</kwd><kwd id="cam470546-kwd-0004">tumor agnostic</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Janssen Research and Development
</institution><institution-id institution-id-type="doi">10.13039/100005205</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="11"/><word-count count="7200"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:26.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="cam470546-ntgp-0001"><fn fn-type="funding" id="cam470546-note-0001"><p>
<bold>Funding:</bold> This work was supported by Janssen Research &#x00026; Development.</p></fn></fn-group></notes></front><body id="cam470546-body-0001"><sec id="cam470546-sec-0005"><label>1</label><title>Introduction</title><p>Fibroblast growth factor receptors (FGFRs) are part of the family of tyrosine kinase receptors and are involved in cell proliferation and growth, among other biological processes [<xref rid="cam470546-bib-0001" ref-type="bibr">1</xref>]. Somatic <italic toggle="yes">FGFR</italic> gene alterations (<italic toggle="yes">FGFRalt</italic>), including <italic toggle="yes">FGFR2</italic> single nucleotide variants (SNVs) and <italic toggle="yes">FGFR2/3</italic> fusions, are proposed to be oncogenic drivers in many solid tumors [<xref rid="cam470546-bib-0002" ref-type="bibr">2</xref>, <xref rid="cam470546-bib-0003" ref-type="bibr">3</xref>, <xref rid="cam470546-bib-0004" ref-type="bibr">4</xref>]. Though seen most commonly in bladder cancer (20%&#x02013;70% in high&#x02010;grade and low&#x02010;grade bladder cancers, respectively), <italic toggle="yes">FGFRalt</italic> occurs at various frequencies across a wide range of malignancies [<xref rid="cam470546-bib-0002" ref-type="bibr">2</xref>, <xref rid="cam470546-bib-0003" ref-type="bibr">3</xref>, <xref rid="cam470546-bib-0005" ref-type="bibr">5</xref>, <xref rid="cam470546-bib-0006" ref-type="bibr">6</xref>, <xref rid="cam470546-bib-0007" ref-type="bibr">7</xref>, <xref rid="cam470546-bib-0008" ref-type="bibr">8</xref>, <xref rid="cam470546-bib-0009" ref-type="bibr">9</xref>], including non&#x02013;small&#x02010;cell lung cancer (NSCLC; <italic toggle="yes">FGFR3/2</italic>, ~3%) [<xref rid="cam470546-bib-0006" ref-type="bibr">6</xref>, <xref rid="cam470546-bib-0007" ref-type="bibr">7</xref>] and cholangiocarcinoma (CCA; 10%&#x02013;16%, <italic toggle="yes">FGFR2</italic> fusion, ~45%) [<xref rid="cam470546-bib-0008" ref-type="bibr">8</xref>, <xref rid="cam470546-bib-0009" ref-type="bibr">9</xref>, <xref rid="cam470546-bib-0010" ref-type="bibr">10</xref>]. Patients with advanced solid tumors in whom <italic toggle="yes">FGFRalt</italic> may be observed [<xref rid="cam470546-bib-0011" ref-type="bibr">11</xref>], in general, have poor outcomes and limited therapeutic options. For patients with many tumor histologies, median survival after diagnosis of advanced or metastatic disease is &#x0003c;&#x02009;1&#x02009;year [<xref rid="cam470546-bib-0012" ref-type="bibr">12</xref>, <xref rid="cam470546-bib-0013" ref-type="bibr">13</xref>, <xref rid="cam470546-bib-0014" ref-type="bibr">14</xref>]. For example, in patients with glioblastoma, in whom <italic toggle="yes">FGFRalt</italic> have been estimated to occur at a frequency of ~3%, treatment with approved second&#x02010;line therapies has resulted in a median survival of 9&#x02009;months [<xref rid="cam470546-bib-0012" ref-type="bibr">12</xref>]. Although prognosis is generally poor for patients with advanced solid tumors with <italic toggle="yes">FGFRalt</italic>, the extent to which <italic toggle="yes">FGFRalt</italic> itself affects prognosis is not fully understood.</p><p>A more comprehensive understanding of the role of oncogenic driver mutations on patient survival has elucidated the potential effects of tailored approaches to treating various solid tumors. For example, NSCLC driven by <italic toggle="yes">EGFR</italic> mutations comprises approximately 15% of all NSCLC in North America; <italic toggle="yes">EGFR</italic> exon 19del or L858R substitution mutations are the most frequently reported (approximately 85% of all <italic toggle="yes">EGFR</italic>&#x02010;mutated NSCLC) [<xref rid="cam470546-bib-0015" ref-type="bibr">15</xref>]. These alterations are associated with increased sensitivity to EGFR tyrosine kinase inhibitors (TKIs), leading to improved prognosis and favorable survival. Similarly, in NSCLC, <italic toggle="yes">STK11</italic> mutations are associated with poor prognosis and resistance to immune checkpoint inhibitors such as PD&#x02010;1/PD&#x02010;L1 inhibitors, and have been linked to a higher likelihood of metastasis and shorter survival [<xref rid="cam470546-bib-0016" ref-type="bibr">16</xref>, <xref rid="cam470546-bib-0017" ref-type="bibr">17</xref>]. In addition, breast cancer studies have used bioinformatics and statistical expression data that have identified key prognostic genes [<xref rid="cam470546-bib-0018" ref-type="bibr">18</xref>, <xref rid="cam470546-bib-0019" ref-type="bibr">19</xref>] and prognostic chemokines [<xref rid="cam470546-bib-0020" ref-type="bibr">20</xref>]. The prognostic impact of <italic toggle="yes">FGFRalt</italic> on survival in patients with urothelial cancer (UC) and CCA has been reported in the literature, with findings showing mixed results, and the prognostic impact of <italic toggle="yes">FGFRalt</italic> in other solid tumors has not been determined comprehensively.</p><p>To date, FGFR&#x02010;targeted therapies have received approvals for histology&#x02010;specific indications (CCA and UC), but not for histology&#x02010;agnostic indications. As the common result of <italic toggle="yes">FGFRalt</italic> across tumor types may be activated FGFR canonical pathway signaling, patients with <italic toggle="yes">FGFRalt</italic>, irrespective of solid tumor type, may benefit from treatment with FGFR inhibitors. Pan&#x02010;FGFR inhibitors, such as infigratinib, futibatinib, and pemigatinib, were granted accelerated approval by the US Food and Drug Administration (FDA) for patients with previously treated, unresectable, locally advanced or metastatic CCA with an <italic toggle="yes">FGFR2</italic> fusion or other rearrangement [<xref rid="cam470546-bib-0021" ref-type="bibr">21</xref>, <xref rid="cam470546-bib-0022" ref-type="bibr">22</xref>, <xref rid="cam470546-bib-0023" ref-type="bibr">23</xref>]. Erdafitinib is a pan&#x02010;FGFR inhibitor approved by the FDA for adult patients with locally advanced or metastatic UC with susceptible <italic toggle="yes">FGFR3</italic> alterations, as determined by an FDA&#x02010;approved companion diagnostic test, whose disease has progressed on or after at least one line of prior systemic therapy, with additional approvals across geographies [<xref rid="cam470546-bib-0024" ref-type="bibr">24</xref>, <xref rid="cam470546-bib-0025" ref-type="bibr">25</xref>, <xref rid="cam470546-bib-0026" ref-type="bibr">26</xref>, <xref rid="cam470546-bib-0027" ref-type="bibr">27</xref>]. RAGNAR (NCT04083976) is an ongoing phase 2, open&#x02010;label, single&#x02010;arm study to examine the safety and efficacy of erdafitinib in patients with advanced solid tumors (excluding UC) with prespecified <italic toggle="yes">FGFRalt</italic> [<xref rid="cam470546-bib-0028" ref-type="bibr">28</xref>]. In the RAGNAR study primary analysis, erdafitinib demonstrated an overall response rate of 30%, a disease control rate of 74%, and a median overall survival (OS) of 10.7&#x02009;months. As RAGNAR is a single&#x02010;arm study with no comparator arm, an understanding of the prognostic value of <italic toggle="yes">FGFRalt</italic> across tumor types can help contextualize the observed outcomes and can facilitate an understanding of the unmet medical need in populations that do not have access to FGFR inhibitors in routine care.</p><p>We report findings of a tumor&#x02010;agnostic observational study aimed to assess the prognostic impact of <italic toggle="yes">FGFRalt</italic> (contextualized to RAGNAR with similarly defined <italic toggle="yes">FGFRalt</italic>) on real&#x02010;world OS (rwOS) of patients in a tumor&#x02010;agnostic setting.</p></sec><sec sec-type="methods" id="cam470546-sec-0006"><label>2</label><title>Methods</title><sec id="cam470546-sec-0007"><label>2.1</label><title>Dataset</title><p>This was a protocol&#x02010;driven, retrospective, observational, comparative cohort analysis using data from the Flatiron Health (FH)&#x02010;Foundation Medicine Inc. (FMI) Clinico&#x02010;Genomic Database (CGDB). FMI directly links de&#x02010;identified comprehensive genomic profiling data and other biomarker data to de&#x02010;identified longitudinal clinical, treatment, and real&#x02010;world outcomes data from FH by de&#x02010;identified, deterministic matching [<xref rid="cam470546-bib-0029" ref-type="bibr">29</xref>]. Advanced/metastatic disease was defined by classifying patients into tumor&#x02010;specific databases or a pan&#x02010;tumor database (as defined in Data&#x000a0;<xref rid="cam470546-supitem-0001" ref-type="supplementary-material">S1</xref>). <italic toggle="yes">FGFR</italic> test results were generated from archival tumors using the FoundationOne CDx (Cambridge, MA) targeted DNA sequencing platform, which included comprehensive genomic profiling of &#x0003e;&#x02009;300 cancer&#x02010;related genes [<xref rid="cam470546-bib-0030" ref-type="bibr">30</xref>]. Notably, this includes <italic toggle="yes">FGFR</italic>1/2/3/4 loci and is designed to sensitively capture small sequence mutations and gene fusions associated with canonical pathway activation in cancer cells. The CGDB is US based and includes patients from more than 280 cancer clinics (~800 sites; primarily community setting) who have undergone genomic testing. Patients were required to have at least two visits recorded in the CGDB to ensure that they were receiving care versus consultation services (consistent with previous analyses of the dataset). The de&#x02010;identified data were subject to obligations to prevent re&#x02010;identification and protect patient confidentiality.</p></sec><sec id="cam470546-sec-0008"><label>2.2</label><title>Inclusion and Exclusion Criteria</title><p>Patients (aged &#x02265;&#x02009;18&#x02009;years) were diagnosed with advanced/metastatic disease between January 1, 2011, and December 31, 2020, had evidence of comprehensive genomic testing for <italic toggle="yes">FGFR</italic> alterations, and had initiated first&#x02010;line systemic treatment for advanced/metastatic disease. Patient distribution by tumor type reflects real&#x02010;world prevalence of <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFR</italic> testing by tumor type and in the CGDB. Tumor types represented in the final analysis dataset included high&#x02010;grade (grade &#x02265;&#x02009;3) glioma, including glioblastoma, CCA, and NSCLC (full listing in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>). Patient exclusion criteria included diagnosis of UC (per alignment with the RAGNAR study [<xref rid="cam470546-bib-0011" ref-type="bibr">11</xref>]) and use of a selective FGFR inhibitor. Additional exclusion criteria are in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>.</p></sec><sec id="cam470546-sec-0009"><label>2.3</label><title>Molecular Diagnostics</title><p>
<italic toggle="yes">FGFRalt</italic> were selected to align with the RAGNAR study [<xref rid="cam470546-bib-0011" ref-type="bibr">11</xref>] and were defined as one or more of 81 prespecified <italic toggle="yes">FGFR</italic> oncogenic driver short sequence mutations or any <italic toggle="yes">FGFR</italic> fusion involving an intact kinase domain (Figure&#x000a0;<xref rid="cam470546-supitem-0001" ref-type="supplementary-material">S1</xref>) [<xref rid="cam470546-bib-0011" ref-type="bibr">11</xref>]. In line with the RAGNAR study, patients with any of the following <italic toggle="yes">FGFR</italic> valine gatekeeper or resistance alterations (alterations that confer resistance to FGFR inhibition) at any time were excluded as kinase domain mutations may drive resistance and bypass tyrosine kinase inhibition [<xref rid="cam470546-bib-0031" ref-type="bibr">31</xref>]: <italic toggle="yes">FGFR1</italic> V561, <italic toggle="yes">FGRF2</italic> V564, <italic toggle="yes">FGFR3</italic> V555, <italic toggle="yes">FGFR4</italic> V550, <italic toggle="yes">FGFR1</italic> N546, <italic toggle="yes">FGFR2</italic> N549, <italic toggle="yes">FGFR3</italic> N540, and <italic toggle="yes">FGFR4</italic> N535. To account for multiple versions of the genomic testing platform used to determine <italic toggle="yes">FGFR</italic> status in the dataset, test version was added as a variable in the Mahalanobis&#x02010;distance matching algorithm used to match patients with <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFR</italic> wild&#x02010;type (<italic toggle="yes">FGFRneg</italic>) tumors.</p></sec><sec id="cam470546-sec-0010"><label>2.4</label><title>Outcome Measures</title><p>The primary endpoint was rwOS, defined as time from the start of first&#x02010;line treatment in the advanced/metastatic setting to death from any cause. Patients for whom death was not recorded were censored at the earliest time they met a prespecified censoring criterion (defined in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>). Briefly, patients who died without meeting any censoring criteria were counted as having a death event. Patients who died but met a censoring criterion prior to death were censored at the earliest time they met the censoring criterion. Deaths that occurred after last clinical activity but before the end of the data cut were counted as outcomes (deaths) rather than censored at last clinical activity (assuming no other censoring criteria were met). Evidence of death was based on several data sources, including external sources linked to the Social Security Death Index and obituary data (defined in the &#x0201c;Mortality capture&#x0201d; section in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>).</p><p>Secondary endpoints were included in an exploratory capacity and included rwOS by tumor type and line of therapy (LOT) and real&#x02010;world time to next treatment (rwTNT) across tumor types, by tumor type, and by LOT (complete list in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>).</p></sec><sec id="cam470546-sec-0011"><label>2.5</label><title>Study Index Date Assignment</title><p>The index dates of patients were assigned as follows:
<list list-type="bullet" id="cam470546-list-0001"><list-item id="cam470546-li-0001"><p>Patients classified into one of the tumor&#x02010;specific databases: Initiation of first&#x02010;line treatment.</p></list-item><list-item id="cam470546-li-0002"><p>Patients classified into the pan&#x02010;tumor database: First non&#x02010;canceled medication order, administration, or abstracted oral therapy after advanced/metastatic diagnosis.</p></list-item></list>
</p><p>Key time periods for the analyses are shown in Figure&#x000a0;<xref rid="cam470546-fig-0001" ref-type="fig">1A</xref>. For analyses for which the start date is first&#x02010;line therapy initiation, the baseline period included all available data prior to first&#x02010;line therapy. For analyses of rwOS and treatment patterns among the subgroups of patients with second&#x02010; and third&#x02010;line therapies for which the index date is second&#x02010; or third&#x02010;line initiation, the baseline periods included all available data prior to second&#x02010; and third&#x02010; line initiation, respectively. There was no minimum requirement for baseline data.</p><fig position="float" fig-type="FIGURE" id="cam470546-fig-0001"><label>FIGURE 1</label><caption><p>(A) Key study time periods and (B) CONSORT diagram including cohort selection criteria across all tumors. 1L, first&#x02010;line; 2L, second&#x02010;line; 3L, third&#x02010;line; <italic toggle="yes">FGFRalt</italic>, fibroblast growth factor receptor gene alterations; <italic toggle="yes">FGFRneg</italic>, fibroblast growth factor receptor gene without mutations or alterations. <sup>a</sup>Date of genomic testing or date of second visit will be used as the delayed entry date if it occurred after initiation of therapy. <sup>b</sup>Using all available data. <sup>c</sup>Exclusion criteria were not mutually exclusive. One patient with <italic toggle="yes">FGFRalt</italic> met two exclusion criteria, resulting in 35 patients being removed.</p></caption><graphic xlink:href="CAM4-14-e70546-g001" position="anchor" id="jats-graphic-3"/></fig><p>Delayed entry models (adjustments for delayed entry left truncation described in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>) were used to mitigate immortal time bias, which could arise because patients included in the analysis needed to survive long enough to be tested for <italic toggle="yes">FGFR</italic> alterations and to have had at least two visits. During this period, the patients could not have died (hence &#x0201c;immortal&#x0201d;) [<xref rid="cam470546-bib-0032" ref-type="bibr">32</xref>]. Patients who died or were lost to follow&#x02010;up before genomic testing or their second visit were excluded. To address potential violations of the assumptions required for delayed entry models, non&#x02010;delayed entry and landmark sensitivity analyses were also included.</p></sec><sec id="cam470546-sec-0012"><label>2.6</label><title>Statistical Analysis</title><p>
<italic toggle="yes">FGFRneg</italic> and <italic toggle="yes">FGFRalt</italic> patient groups were matched 3:1 based on tumor type, age/date of advanced/metastatic diagnosis, sex, and genomic test platform version using a combination of exact (tumor type; note that disease type classifications are defined by the clinical study protocol NCT04083976) [<xref rid="cam470546-bib-0028" ref-type="bibr">28</xref>] and Mahalanobis&#x02010;distance (all other select matching variables) matching (list and rationale for used variable selection in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>). Due to exact matching by tumor type, both <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> groups had exactly the same distribution of tumor types.</p><p>The hazard ratio (HR) comparing rwOS for the <italic toggle="yes">FGFRalt/FGFRneg</italic> patient groups was estimated for the matched data using a Cox proportional hazards model accounting for delayed entry. A tumor&#x02010;type stratified Cox model was used for the primary analysis to account for presumed differences in baseline hazard functions for the different tumor types. An unstratified Cox model was included as a sensitivity analysis, which, together with additional sensitivity analyses, is described in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>. Cox models were adjusted for additional covariates of interest. In the event that there were model convergence issues due to small sample sizes (<italic toggle="yes">n</italic>&#x02009;&#x0003c;&#x02009;10 patients) or a small number of events, tumor types with small sizes were grouped together to achieve <italic toggle="yes">n</italic>&#x02009;&#x02265;&#x02009;10 patients, per protocol.</p><p>Prespecified covariates of interest included in the Cox models were tumor stage, tumor mutational burden (TMB), Eastern Cooperative Oncology Group performance status (ECOG PS), Charlson Comorbidity Index (CCI), smoking history, diagnosis of cancer at advanced/metastatic disease (vs prior to advanced/metastatic disease), number of prior LOTs (i.e., systemic therapies prior to the diagnosis of metastatic disease), and previous medications. Selection was based on clinical judgment (e.g., the potential to be a confounder on the causal pathway from <italic toggle="yes">FGFR</italic> status to survival), published literature, data availability, and differences in cohort distributions. Standardized mean differences (SMDs) were used to determine the balance of variables post matching, with variables achieving an absolute SMD &#x0003c;&#x02009;0.10 deemed balanced [<xref rid="cam470546-bib-0033" ref-type="bibr">33</xref>, <xref rid="cam470546-bib-0034" ref-type="bibr">34</xref>].</p><p>The study was statistically powered for the primary endpoint of rwOS in the tumor&#x02010;agnostic setting. Due to the rarity of qualifying target <italic toggle="yes">FGFR</italic> mutations and fusions, the availability of <italic toggle="yes">FGFRalt</italic> patient source data was used for sample size consideration, with power calculations used to select the number of matches for each patient with <italic toggle="yes">FGFRalt</italic> (Table&#x000a0;<xref rid="cam470546-supitem-0001" ref-type="supplementary-material">S1</xref>). No corrections for multiple hypothesis testing were implemented.</p><p>Censoring rules are provided in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref>.</p></sec></sec><sec sec-type="results" id="cam470546-sec-0013"><label>3</label><title>Results</title><sec id="cam470546-sec-0014"><label>3.1</label><title>Patient Characteristics</title><p>Data from 1435 patients (359 <italic toggle="yes">FGFRalt</italic> and 1076 matched <italic toggle="yes">FGFRneg</italic>) were available in the CGDB (Figure&#x000a0;<xref rid="cam470546-fig-0001" ref-type="fig">1B</xref>). After data ingestion, a subset of patients was removed from the analysis dataset, prior to analysis, because they met the exclusion criteria stated in the protocol or due to matching considerations (e.g., removing all <italic toggle="yes">FGFRneg</italic> matches to a patient with <italic toggle="yes">FGFRalt</italic> who was removed due to meeting an exclusion criteria). The final analysis set comprised 1012 patients (253 <italic toggle="yes">FGFRalt</italic>, 759 <italic toggle="yes">FGFRneg</italic>).</p><p>All variables used for matching patients with <italic toggle="yes">FGFRalt</italic> and those who are <italic toggle="yes">FGFRneg</italic> (tumor type, age/date of advanced/metastatic diagnosis, sex, and genomic test platform version) were balanced after matching, achieving a post&#x02010;matching absolute standardized difference in means/proportions &#x0003c;&#x02009;0.10. Smoking history, time from advanced/metastatic disease diagnosis to frontline treatment initiation, ECOG PS values, and modified CCI score were balanced across groups (Table&#x000a0;<xref rid="cam470546-tbl-0001" ref-type="table">1</xref> [unmatched data in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Table&#x000a0;S2</xref>] and Table&#x000a0;<xref rid="cam470546-supitem-0001" ref-type="supplementary-material">S3</xref>; <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Table&#x000a0;S4</xref> by mutation or fusion for <italic toggle="yes">FGFRalt</italic>). Variables that had absolute SMDs &#x0003e;&#x02009;0.10 after matching included race (White and other categories), group stage at initial diagnosis (stages 2 and 4), TMB, and components of the CCI, including prior myocardial infarction, congestive heart failure, and mild chronic liver disease (see Table&#x000a0;<xref rid="cam470546-tbl-0001" ref-type="table">1</xref> and <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Table&#x000a0;S3</xref>; <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Table&#x000a0;S4</xref> by mutation or fusion for the full list of variables). Covariate adjustment was used to mitigate any residual imbalances in variables after matching. The most common treatment regimens by LOT for specific tumor types are shown in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Table&#x000a0;S5</xref>. The median (interquartile range) number of LOTs that patients underwent was 2 (1&#x02010;3) in both the <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> groups and was balanced across tumor types. There were 30 different tumor types included in the final analysis set. CCA, NSCLC, and breast cancer were the most prevalent entities (Table&#x000a0;<xref rid="cam470546-tbl-0002" ref-type="table">2</xref>). The most common <italic toggle="yes">FGFR</italic> fusions and mutations varied across tumor types (<xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Table&#x000a0;S6</xref>).</p><table-wrap position="float" id="cam470546-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Demographic and baseline characteristics of <italic toggle="no">FGFRalt/FGFRneg</italic> groups across all tumors.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">FGFRalt</italic> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;253)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">FGFRneg</italic> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;759)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Absolute standardized difference in means/proportions</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="4" valign="top" rowspan="1">Demographic characteristics among all tumors</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at advanced/metastatic diagnosis Median (range), years</td><td align="center" valign="top" rowspan="1" colspan="1">62 (18&#x02013;84)</td><td align="center" valign="top" rowspan="1" colspan="1">63 (28&#x02013;85)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;65&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">147 (58.1)</td><td align="center" valign="top" rowspan="1" colspan="1">426 (56.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">&#x02265;&#x02009;65&#x02009;years</td><td align="center" valign="top" rowspan="1" colspan="1">106 (41.9)</td><td align="center" valign="top" rowspan="1" colspan="1">333 (43.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="center" colspan="3" valign="top" rowspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Male</td><td align="center" valign="top" rowspan="1" colspan="1">113 (44.7)</td><td align="center" valign="top" rowspan="1" colspan="1">339 (44.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Female</td><td align="center" valign="top" rowspan="1" colspan="1">140 (55.3)</td><td align="center" valign="top" rowspan="1" colspan="1">420 (55.3)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race</td><td align="center" colspan="3" valign="top" rowspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">White</td><td align="center" valign="top" rowspan="1" colspan="1">183 (72.3)</td><td align="center" valign="top" rowspan="1" colspan="1">503 (66.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Black or African American</td><td align="center" valign="top" rowspan="1" colspan="1">21 (8.3)</td><td align="center" valign="top" rowspan="1" colspan="1">53 (7.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Asian</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">18 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hispanic or Latino</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other</td><td align="center" valign="top" rowspan="1" colspan="1">30 (11.9)</td><td align="center" valign="top" rowspan="1" colspan="1">127 (16.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">14 (5.5)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (7.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking history</td><td align="center" colspan="3" valign="top" rowspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<p>Yes</p>
<p>No</p>
<p>Unknown</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>140 (55.3)</p>
<p>113 (44.7)</p>
<p>0 (0.0)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>438 (57.7)</p>
<p>319 (42.0)</p>
<p>2 (0.3)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.05</p>
<p>0.05</p>
<p>0.07</p>
</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Clinical characteristics among all tumors</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" valign="top" rowspan="1">Group stage at initial diagnosis</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Group stage 0</td><td align="center" valign="top" rowspan="1" colspan="1">18 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Group stage 1</td><td align="center" valign="top" rowspan="1" colspan="1">27 (10.7)</td><td align="center" valign="top" rowspan="1" colspan="1">87 (11.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Group stage 2</td><td align="center" valign="top" rowspan="1" colspan="1">51 (20.2)</td><td align="center" valign="top" rowspan="1" colspan="1">109 (14.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Group stage 3</td><td align="center" valign="top" rowspan="1" colspan="1">128 (50.6)</td><td align="center" valign="top" rowspan="1" colspan="1">385 (50.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.00</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Group stage 4</td><td align="center" valign="top" rowspan="1" colspan="1">29 (11.5)</td><td align="center" valign="top" rowspan="1" colspan="1">123 (16.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor mutational burden (version 1)<xref rid="cam470546-note-0004" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">43 (17.0)</td><td align="center" valign="top" rowspan="1" colspan="1">152 (20.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median (IQR)</td><td align="center" valign="top" rowspan="1" colspan="1">6.09 (1.25&#x02013;15.66)</td><td align="center" valign="top" rowspan="1" colspan="1">4.35 (1.93&#x02013;8.63)</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor mutational burden (version 2)<xref rid="cam470546-note-0005" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">41 (16.2)</td><td align="center" valign="top" rowspan="1" colspan="1">133 (17.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median (IQR)</td><td align="center" valign="top" rowspan="1" colspan="1">7.02 (1.25&#x02013;15.76)</td><td align="center" valign="top" rowspan="1" colspan="1">5.04 (2.52&#x02013;9.65)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time from advanced/metastatic disease to first systemic treatment</td><td align="center" valign="top" rowspan="1" colspan="1">252 (99.6)</td><td align="center" valign="top" rowspan="1" colspan="1">747 (98.4)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median (IQR), months</td><td align="center" valign="top" rowspan="1" colspan="1">31.50 (16.25&#x02013;54.0)</td><td align="center" valign="top" rowspan="1" colspan="1">29.0 (16.0&#x02013;50.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" colspan="4" valign="top" rowspan="1">Clinical characteristics at baseline</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">ECOG PS</td><td align="center" colspan="3" valign="top" rowspan="1"/></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">81 (32.0)</td><td align="center" valign="top" rowspan="1" colspan="1">238 (31.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">80 (31.6)</td><td align="center" valign="top" rowspan="1" colspan="1">212 (27.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">2</td><td align="center" valign="top" rowspan="1" colspan="1">19 (7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">50 (6.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">6 (2.4)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" style="padding-left:15%" valign="top" rowspan="1" colspan="1">Missing</td><td align="center" valign="top" rowspan="1" colspan="1">67 (26.5)</td><td align="center" valign="top" rowspan="1" colspan="1">244 (32.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Modified CCI score</p>
<p>Median (IQR)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (0.0&#x02013;2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.00 (0.0&#x02013;2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.08</p>
</td></tr></tbody></table><table-wrap-foot id="cam470546-ntgp-0002"><fn id="cam470546-note-0002"><p>
<italic toggle="yes">Note:</italic> All values are <italic toggle="yes">n</italic> (%) except where otherwise noted. Variables used in the matching algorithm were balanced between <italic toggle="yes">FGFRalt</italic>/<italic toggle="yes">FGFRneg</italic> groups in the analyses of all patients but may have become unbalanced in analyses of patient subgroups who initiated second&#x02010; and third&#x02010;line treatment, and patient subgroups based on treatment type for specific tumor types. Imbalances were accounted for by including the variables used for matching in multivariate covariate adjustment.</p></fn><fn id="cam470546-note-0003"><p>Abbreviations: CCI, Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; <italic toggle="yes">FGFRalt</italic>, fibroblast growth factor receptor gene alterations; <italic toggle="yes">FGFRneg</italic>, fibroblast growth factor receptor gene without mutations or alterations; IQR, interquartile range.</p></fn><fn id="cam470546-note-0004"><label>
<sup>a</sup>
</label><p>Version 1 approximates the tumor mutational burden score from running all samples and is biomarker&#x02010;harmonized to incorporate recent scientific understanding.</p></fn><fn id="cam470546-note-0005"><label>
<sup>b</sup>
</label><p>Version 2 approximates clinically reported values and the variant annotations used are based on latest scientific understanding at the time of reporting.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="cam470546-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Distribution of tumor types in all patients.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Tumor type</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">FGFRalt</italic> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;253)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">FGFRneg</italic> (<italic toggle="yes">n</italic>&#x02009;=&#x02009;759)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Total (<italic toggle="yes">N</italic>&#x02009;=&#x02009;1012)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Tumor&#x02010;specific databases<xref rid="cam470546-note-0008" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" colspan="3" valign="top" rowspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Cholangiocarcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">66 (26.1)</td><td align="center" valign="top" rowspan="1" colspan="1">198 (26.1)</td><td align="center" valign="top" rowspan="1" colspan="1">264 (26.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;small cell lung cancer</td><td align="center" valign="top" rowspan="1" colspan="1">45 (17.8)</td><td align="center" valign="top" rowspan="1" colspan="1">135 (17.8)</td><td align="center" valign="top" rowspan="1" colspan="1">180 (17.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Breast cancer</td><td align="center" valign="top" rowspan="1" colspan="1">32 (12.6)</td><td align="center" valign="top" rowspan="1" colspan="1">96 (12.6)</td><td align="center" valign="top" rowspan="1" colspan="1">128 (12.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gastric/esophagogastric cancer</td><td align="center" valign="top" rowspan="1" colspan="1">15 (5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">45 (5.9)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (5.9)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" valign="top" rowspan="1" colspan="1">13 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">52 (5.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="top" rowspan="1" colspan="1">12 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">48 (4.7)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Endometrial cancer</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">27 (3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (3.6)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Head and neck cancer</td><td align="center" valign="top" rowspan="1" colspan="1">7 (2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (2.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Pancreatic cancer</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">20 (2.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Ovarian cancer</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (1.2)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="center" valign="top" rowspan="1" colspan="1">2 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (0.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Small cell lung cancer</td><td align="center" valign="top" rowspan="1" colspan="1">2 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">6 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (0.8)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Prostate cancer</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (0.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pan&#x02010;tumor database<xref rid="cam470546-note-0009" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" colspan="3" valign="top" rowspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Glioblastoma</td><td align="center" valign="top" rowspan="1" colspan="1">11 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">33 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">44 (4.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Carcinoma: Gyn: Cervical</td><td align="center" valign="top" rowspan="1" colspan="1">10 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">30 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">40 (4.0)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Other<xref rid="cam470546-note-0010" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">20 (7.9)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (7.9)</td><td align="center" valign="top" rowspan="1" colspan="1">80 (7.9)</td></tr></tbody></table><table-wrap-foot id="cam470546-ntgp-0003"><fn id="cam470546-note-0006"><p>
<italic toggle="yes">Note:</italic> All values are <italic toggle="yes">n</italic> (%).</p></fn><fn id="cam470546-note-0007"><p>Abbreviations: <italic toggle="yes">FGFRalt</italic>, fibroblast growth factor receptor gene alterations; <italic toggle="yes">FGFRneg</italic>, fibroblast growth factor receptor gene without mutations or alterations.</p></fn><fn id="cam470546-note-0008"><label>
<sup>a</sup>
</label><p>The Clinico&#x02010;Genomic Database includes patients with both a confirmed diagnosis of advanced or metastatic cancer and an available <italic toggle="yes">FGFRalt</italic> status. Additional criteria are required for a patient to qualify for a tumor&#x02010;specific database. Tumor&#x02010;specific databases include those shown plus renal cell carcinoma.</p></fn><fn id="cam470546-note-0009"><label>
<sup>b</sup>
</label><p>If the patient is not eligible for any tumor&#x02010;specific database, the patient becomes eligible for the pan&#x02010;tumor database. With this hierarchy, a patient cannot exist in both a tumor&#x02010;specific database and the pan&#x02010;tumor database.</p></fn><fn id="cam470546-note-0010"><label>
<sup>c</sup>
</label><p>Other includes (<italic toggle="yes">FGFRalt</italic>/<italic toggle="yes">FGFRneg</italic>; <italic toggle="yes">n</italic>): Cervical carcinoma (10/30); anal carcinoma (3/9); vaginal carcinoma (3/9); carcinoma of the head and neck (3/9); gastrointestinal (gastric, colon, rectum, appendix, small intestine) (2/6); gallbladder carcinoma (1/3); cutaneous squamous cell carcinoma (1/3); papillary/follicular thyroid carcinoma (1/3); non&#x02010;cutaneous (mucosal, uveal, etc) (1/3); osteosarcoma (1/3); unspecified/other soft&#x02010;tissue sarcoma, liposarcoma, unspecified/other bone sarcoma, angiosarcoma, unspecified/other sarcoma, or non&#x02010;uterine leiomyosarcoma (4/12).</p></fn></table-wrap-foot></table-wrap><p>Of the 253 patients who had <italic toggle="yes">FGFRalt</italic>, 142 had <italic toggle="yes">FGFR</italic> fusions and 110 had <italic toggle="yes">FGFR1&#x02010;3</italic> mutations; 1 patient had both. Of the 142 patients who had <italic toggle="yes">FGFR</italic> fusions, 86 (60.6%) had <italic toggle="yes">FGFR2</italic> fusions, 48 (33.8%) had <italic toggle="yes">FGFR3</italic> fusions, and 8 (5.6%) had <italic toggle="yes">FGFR1</italic> fusions. Of the 110 patients who had <italic toggle="yes">FGFR1&#x02013;3</italic> mutations, 69 (62.7%) had <italic toggle="yes">FGFR2</italic> mutations, 40 (36.4%) had <italic toggle="yes">FGFR3</italic> mutations, and 7 (6.4%) had <italic toggle="yes">FGFR1</italic> mutations. The most common <italic toggle="yes">FGFR1&#x02013;3</italic> mutations were <italic toggle="yes">FGFR3</italic> S249C (27 [24.5%]), <italic toggle="yes">FGFR3</italic> R248C (9 [8.2%]), and <italic toggle="yes">FGFR2</italic> C382R (7 [6.4%]).</p></sec><sec id="cam470546-sec-0015"><label>3.2</label><title>Primary Endpoint: rwOS From First&#x02010;Line Therapy Across all Tumor Types</title><p>Median rwOS from first&#x02010;line treatment across all tumor types was 1.13&#x02009;years (95% CI 0.92&#x02013;1.52) in the <italic toggle="yes">FGFRalt</italic> group compared with 1.01&#x02009;years (95% CI 0.89&#x02013;1.15) for <italic toggle="yes">FGFRneg</italic> (Figure&#x000a0;<xref rid="cam470546-fig-0002" ref-type="fig">2A</xref>). rwOS from first&#x02010;line therapy across all tumor types was not significantly different for patients with <italic toggle="yes">FGFRalt</italic> versus those with <italic toggle="yes">FGFRneg</italic> tumors in the primary analysis, for any of the statistical models used, including stratified Cox models fully adjusted for covariates (HR 0.97; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.78), unadjusted stratified Cox models (HR 0.95; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.64), and minimally adjusted, stratified Cox models (HR 0.99; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.96). HRs &#x0003c;&#x02009;1 correspond to a protective effect of <italic toggle="yes">FGFRalt</italic>.</p><fig position="float" fig-type="FIGURE" id="cam470546-fig-0002"><label>FIGURE 2</label><caption><p>rwOS from first&#x02010;line therapy. (A) Kaplan&#x02013;Meier curves across all tumor types and (B) by tumor type. A tumor&#x02010;type stratified Cox model accounting for delayed entry was used for the primary analysis. In the <italic toggle="yes">FGFRneg</italic> group, the number at risk increases from 0 to 1&#x02009;year because genomic test dates for some patients occurred after first&#x02010;line initiation, and therefore those patients entered the risk set after the first&#x02010;line initiation date. 1L, first&#x02010;line; CI, confidence interval; <italic toggle="yes">FGFRalt</italic>, fibroblast growth factor receptor gene alterations; <italic toggle="yes">FGFRneg</italic>, fibroblast growth factor receptor gene without mutations or alterations; GBM, glioblastoma; GEJ, gastroesophageal junction; HR, hazard ratio; NSCLC, non&#x02010;small cell lung cancer. <sup>a</sup>Unadjusted model did not include covariates. <sup>b</sup>Minimally adjusted for covariates of interest: Tumor type, age at advanced diagnosis, year of advanced diagnosis (categorical), sex, and Foundation Medicine Inc. (FMI) test version (dichotomous). <sup>c</sup>Fully adjusted for covariates of interest: Tumor type, age at advanced diagnosis, year of advanced diagnosis (categorical), sex, FMI test version (dichotomous), group stage, diagnosed early versus advanced (dichotomous), Charlson Comorbidity Index, and smoking status.</p></caption><graphic xlink:href="CAM4-14-e70546-g003" position="anchor" id="jats-graphic-5"/></fig></sec><sec id="cam470546-sec-0016"><label>3.3</label><title>Secondary Endpoints</title><sec id="cam470546-sec-0017"><label>3.3.1</label><title>rwOS By Tumor Type and LOT</title><p>rwOS by tumor type was not significantly different between the <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> groups (Figure&#x000a0;<xref rid="cam470546-fig-0002" ref-type="fig">2B</xref>). Median rwOS ranged from 0.78&#x02009;years in CCA to 2.15&#x02009;years in melanoma.</p><p>rwOS from second&#x02010; and third&#x02010;line therapy was not significantly different among patients with <italic toggle="yes">FGFRalt</italic> and those with <italic toggle="yes">FGFRneg</italic> tumors (Table&#x000a0;<xref rid="cam470546-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="cam470546-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Secondary endpoints (A) rwOS by LOT (B) rwTNT for <italic toggle="no">FGFRalt/FGFRneg</italic> patients across all tumors and by subgroups of tumor types.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1"/><th align="center" colspan="2" valign="bottom" rowspan="1">Median, years (95% CI)</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">FGFRalt/FGFRneg</italic> HR (95% CI)<xref rid="cam470546-note-0012" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" rowspan="2" valign="bottom" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">FGFRalt</italic>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">FGFRneg</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="5" valign="top" rowspan="1">rwOS by LOT across all tumor types</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Second&#x02010;line therapy, <italic toggle="yes">n</italic>&#x02009;=&#x02009;508</td><td align="center" valign="top" rowspan="1" colspan="1">0.75 (0.52&#x02013;1.08)</td><td align="center" valign="top" rowspan="1" colspan="1">0.77 (0.64&#x02013;1.08)</td><td align="center" valign="top" rowspan="1" colspan="1">1.06 (0.78&#x02013;1.44)<xref rid="cam470546-note-0013" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Third&#x02010;line therapy, <italic toggle="yes">n</italic>&#x02009;=&#x02009;280</td><td align="center" valign="top" rowspan="1" colspan="1">0.57 (0.36&#x02013;1.60)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.58&#x02013;1.11)</td><td align="center" valign="top" rowspan="1" colspan="1">1.22 (0.81&#x02013;1.86)<xref rid="cam470546-note-0013" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" colspan="5" valign="top" rowspan="1">rwTNT from first&#x02010;to&#x02010;second&#x02010;line therapy</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Across all tumors</td><td align="center" valign="top" rowspan="1" colspan="1">0.77 (0.59&#x02013;0.89)</td><td align="center" valign="top" rowspan="1" colspan="1">0.73 (0.67&#x02013;0.82)</td><td align="center" valign="top" rowspan="1" colspan="1">1.07 (0.87&#x02013;1.32)<xref rid="cam470546-note-0013" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.50</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">By tumor type</td><td align="center" colspan="4" valign="top" rowspan="1"/></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<p>Breast cancer, <italic toggle="yes">n</italic>&#x02009;=&#x02009;128</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.45 (0.32&#x02013;1.34)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.56 (0.46&#x02013;0.81)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.17 (0.72&#x02013;1.92)<xref rid="cam470546-note-0014" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">
<p>Cholangiocarcinoma, <italic toggle="yes">n</italic>&#x02009;=&#x02009;264</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.59 (0.46&#x02013;1.03)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.68 (0.63&#x02013;0.83)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.13 (0.77&#x02013;1.66)<xref rid="cam470546-note-0014" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Colorectal cancer, <italic toggle="yes">n</italic>&#x02009;=&#x02009;52</td><td align="center" valign="top" rowspan="1" colspan="1">0.79 (0.52&#x02013;NA)</td><td align="center" valign="top" rowspan="1" colspan="1">0.82 (0.65&#x02013;1.65)</td><td align="center" valign="top" rowspan="1" colspan="1">3.88 (1.20&#x02013;12.55)<xref rid="cam470546-note-0014" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Gastric/esophagogastric junction cancer, <italic toggle="yes">n</italic>&#x02009;=&#x02009;60</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>0.91 (0.46&#x02013;NA)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.56 (0.46&#x02013;0.84)</td><td align="center" valign="top" rowspan="1" colspan="1">0.27 (0.09&#x02013;0.85)<xref rid="cam470546-note-0014" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Melanoma, <italic toggle="yes">n</italic>&#x02009;=&#x02009;48</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>NA (0.59&#x02013;NA)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<p>1.90 (0.86&#x02013;NA)</p>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.36 (0.25&#x02013;7.34)<xref rid="cam470546-note-0014" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Non&#x02010;small cell lung cancer, <italic toggle="yes">n</italic>&#x02009;=&#x02009;180</td><td align="center" valign="top" rowspan="1" colspan="1">0.84 (0.68&#x02013;NA)</td><td align="center" valign="top" rowspan="1" colspan="1">1.26 (0.78&#x02013;1.79)</td><td align="center" valign="top" rowspan="1" colspan="1">1.45 (0.86&#x02013;2.45)<xref rid="cam470546-note-0014" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.17</td></tr></tbody></table><table-wrap-foot id="cam470546-ntgp-0004"><fn id="cam470546-note-0011"><p>Abbreviations: CI, confidence interval; <italic toggle="yes">FGFRalt</italic>, fibroblast growth factor receptor gene alterations; <italic toggle="yes">FGFRneg</italic>, fibroblast growth factor receptor gene without mutations or alterations; HR, hazard ratio; NA, not applicable; rwTNT, real&#x02010;world time to next treatment.</p></fn><fn id="cam470546-note-0012"><label>
<sup>a</sup>
</label><p>Fully adjusted for covariates of interest: Tumor type, age at advanced diagnosis, year of advanced diagnosis (categorical), sex, Foundation Medicine Inc. (FMI) test version (dichotomous), group stage, diagnosed early versus advanced (dichotomous), Charlson Comorbidity Index, and smoking status.</p></fn><fn id="cam470546-note-0013"><label>
<sup>b</sup>
</label><p>A tumor&#x02010;type stratified Cox model accounting for delayed entry.</p></fn><fn id="cam470546-note-0014"><label>
<sup>c</sup>
</label><p>A standard Cox model not accounting for delayed entry.</p></fn></table-wrap-foot></table-wrap></sec><sec id="cam470546-sec-0018"><label>3.3.2</label><title>rwTNT Across all Tumor Types, by Tumor Type, and by LOT</title><p>rwTNT from first&#x02010; to second&#x02010;line therapy was not significantly different among patients in the <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> groups across all tumor types (HR 1.07; 95% CI 0.87&#x02013;1.32; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.5) (Table&#x000a0;<xref rid="cam470546-tbl-0003" ref-type="table">3</xref>). Median rwTNT from first&#x02010; to second&#x02010;line therapy was 0.77&#x02009;years for <italic toggle="yes">FGFRalt</italic> compared with 0.73&#x02009;years for <italic toggle="yes">FGFRneg</italic>. rwTNT from first&#x02010; to second&#x02010;line therapy was significantly different among <italic toggle="yes">FGFRalt</italic> patients compared with <italic toggle="yes">FGFRneg</italic> patients with colorectal cancer, with patients with <italic toggle="yes">FGFRalt</italic> having worse outcomes than those who were <italic toggle="yes">FGFRneg</italic> (HR 3.88; 95% CI 1.20&#x02013;12.55; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.02), whereas better outcomes were seen among patients with <italic toggle="yes">FGFRalt</italic> gastric/esophagogastric junction cancer (HR 0.27; 95% CI 0.09&#x02013;0.85; <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.03) compared with those who were <italic toggle="yes">FGFRneg</italic>.</p><p>Additional secondary endpoints, sensitivity analyses, and genomic landscape co&#x02010;alterations are described in <xref rid="cam470546-supitem-0001" ref-type="supplementary-material">Data S1</xref> and shown in Figures&#x000a0;<xref rid="cam470546-supitem-0001" ref-type="supplementary-material">S2&#x02013;S4</xref> and Tables&#x000a0;<xref rid="cam470546-supitem-0001" ref-type="supplementary-material">S7&#x02013;S14</xref>.</p></sec></sec></sec><sec sec-type="discussion" id="cam470546-sec-0019"><label>4</label><title>Discussion</title><p>No statistically significant differences in rwOS were observed between matched patients with advanced <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> solid tumors treated with non&#x02013;FGFR&#x02010;targeted therapy. The HR for rwOS between <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> patients for the primary endpoint was 0.97 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.78), and alternative statistical models yielded results consistent with those seen in the primary analysis. These results indicate that, in the real&#x02010;world setting, patients whose tumors are driven by FGFR signaling have outcomes similar to those of patients whose tumors have different genetic drivers (for tumor types included in this analysis). Kaplan&#x02013;Meier survival curves for both groups were similar; median rwOS was 1.13&#x02009;years from first&#x02010;line therapy for patients with <italic toggle="yes">FGFRalt</italic> and 1.01&#x02009;years from first&#x02010;line therapy for patients who were <italic toggle="yes">FGFRneg</italic>. Statistically significant differences in rwOS by individual tumor type were not observed between the <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> groups, although the analysis was not powered for a tumor&#x02010;specific comparison. These data suggest that patients with <italic toggle="yes">FGFRalt</italic> have similarly poor OS in the advanced or metastatic setting as <italic toggle="yes">FGFRneg</italic> patients, highlighting the high unmet need and potential of FGFR&#x02010;targeting agents to improve outcomes.</p><p>Although <italic toggle="yes">FGFRalt</italic> are observed in many tumor types, previous studies were limited to select tumor types. Previous studies also had methodological challenges, including small sample size and imbalances in confounders [<xref rid="cam470546-bib-0035" ref-type="bibr">35</xref>, <xref rid="cam470546-bib-0036" ref-type="bibr">36</xref>]. These limitations underscore the need for a rigorous pan&#x02010;tumor evaluation of how <italic toggle="yes">FGFRalt</italic> impact prognosis in patients with advanced/metastatic disease.</p><p>The present study has several key strengths: it was a large observational comparative study with the primary objective of investigating the prognostic value of pathogenic <italic toggle="yes">FGFRalt</italic> versus <italic toggle="yes">FGFRneg</italic> in patients with advanced solid tumors in a statistically robust manner. Also, the definition of <italic toggle="yes">FGFRalt</italic> was normalized to those patients in whom FGFR is most likely to be a driving event in cancer development and progression. The study was protocol driven and designed with statistical power to evaluate any differences in rwOS of <italic toggle="yes">FGFRalt</italic> patients compared with <italic toggle="yes">FGFRneg</italic> patients. The study utilized a number of statistical methods, including patient matching on known confounders, delayed entry modeling of survival outcomes, and covariate&#x02010;adjusted stratified Cox modeling, to minimize bias and ensure rigor.</p><p>A limitation of this study is the exclusion of patients with UC, thus limiting the generalizability of the results. However, UC has been studied previously, with similar results showing no significant difference observed in OS when comparing <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> [<xref rid="cam470546-bib-0037" ref-type="bibr">37</xref>]. In addition, the FoundationOne CDx test versions did not assess <italic toggle="yes">FGFR4</italic> alterations, which may have led to misclassified <italic toggle="yes">FGFRalt</italic> status. However, given the rarity of <italic toggle="yes">FGFR4</italic> alterations (&#x0003c;&#x02009;0.04% frequency in GENIE databases, September 2022), the number of misclassified patients was likely small. <italic toggle="yes">FGFR</italic> testing is not standard of care for most tumor types; therefore, it is likely that tumor types for which <italic toggle="yes">FGFR</italic> testing is not commonly undertaken may have been underrepresented. Comorbidity information may have been incomplete as electronic health records were not oncology specific. This study was not powered to measure tumor&#x02010;specific outcomes, and therefore conclusions regarding these outcomes are limited. Patients might have been lost to follow&#x02010;up and mortality may have been underestimated. Delayed entry was accounted for in the primary models of rwOS to avoid biasing the study results; however, delayed entry was not accounted for when modeling other outcomes, and therefore the results may have been biased if timing of genetic testing relative to outcomes differed by cohort. There was a low proportion of patients with reported TMB score data, comprising &#x02264;&#x02009;20% of patients in each cohort when confidence in the computed score did not meet the necessary threshold. High levels of absent TMB data could lead to biased HR estimates if in reality there were differential TMB levels between the <italic toggle="yes">FGFRalt</italic> and <italic toggle="yes">FGFRneg</italic> groups.</p><p>This analysis included only patients who were treated with systemic anticancer therapy after advanced/metastatic diagnosis, and thus excluded patients who were not treated with systemic anticancer therapy after advanced/metastatic disease. These untreated patients may have had poor prognosis (e.g., not candidates for any systemic therapy due to poor performance status). Thus, the analysis may have excluded a subset of patients with poor outcomes. Only patients who were statistically matched were included in the study; differences in unmatched/matched patients resulting from unmeasured confounders may have led to biased estimation if key prognostic factors were not included in subsequent covariate&#x02010;adjusted models.</p><p>This study examined the prognostic role of <italic toggle="yes">FGFRalt</italic>, independent of other genetic alterations, on survival outcomes. The cooperative impact on tumor growth and progression of <italic toggle="yes">FGFRalt</italic> and other mutations, such as those in other canonical pathways, have not been thoroughly evaluated; for example, in solid tumors with high microsatellite instability, in which immune checkpoint inhibitors have demonstrated superior clinical outcomes in select tumor types, including colorectal cancer.</p><p>In this statistically powered and matched&#x02010;cohort real&#x02010;world analysis, there was no significant difference in rwOS between patients with <italic toggle="yes">FGFRalt or FGFRneg</italic> advanced/metastatic solid tumors; median OS was approximately 1&#x02009;year in both groups. These results highlight the poor prognosis and high unmet need for novel and targeted therapies in these patient populations.</p></sec><sec id="cam470546-sec-0025"><title>Author Contributions</title><p>
<bold>Levon Demirdjian:</bold> conceptualization (lead), data curation (lead), formal analysis (lead), investigation (lead), methodology (lead), project administration (equal), writing &#x02013; original draft (lead), writing &#x02013; review and editing (lead). <bold>Spyros Triantos:</bold> conceptualization (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Kristopher Standish:</bold> data curation (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Shibu Thomas:</bold> conceptualization (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Qi Xia:</bold> conceptualization (equal), data curation (equal), formal analysis (equal), investigation (equal), writing &#x02013; review and editing (equal). <bold>Jiarui Zhang:</bold> conceptualization (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Joel Greshock:</bold> conceptualization (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Julie Paone:</bold> conceptualization (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Paige Sheridan:</bold> conceptualization (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal). <bold>Shubham Pant:</bold> formal analysis (equal), writing &#x02013; review and editing (equal). <bold>Christophe Massard:</bold> formal analysis (equal), writing &#x02013; original draft (equal), writing &#x02013; review and editing (equal). <bold>David A. Reardon:</bold> formal analysis (equal), writing &#x02013; review and editing (equal). <bold>Yohann Loriot:</bold> formal analysis (equal), writing &#x02013; review and editing (equal). <bold>Martin Schuler:</bold> formal analysis (equal), writing &#x02013; review and editing (equal). <bold>Hussein Sweiti:</bold> conceptualization (equal), formal analysis (equal), investigation (equal), methodology (equal), writing &#x02013; review and editing (equal).</p></sec><sec id="cam470546-sec-0021"><title>Ethics Statement</title><p>To ensure privacy of the patient&#x02010;level information, all analyses were conducted only using de&#x02010;identified, commercially available patient data. Confidentiality of patient records was maintained at all times. All study reports contained aggregate data only.</p></sec><sec sec-type="COI-statement" id="cam470546-sec-0022"><title>Conflicts of Interest</title><p>L.D., S.T., K.S., C.H., S.T., Q.X., J.Z., J.G., and H.S. received personal fees from Janssen during the conduct of the study. J.P. and P.S. received personal fees from Aetion during the conduct of the study. S.P. has received consulting fees from Ipsen, Janssen, Novartis, and Zymeworks; and institutional research funding from 4D Pharma, Arcus Biosciences, Astellas Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Elicio Therapeutics, Janssen, Lilly, Mirati Therapeutics, NGM Biopharmaceuticals, Novartis, Purple Biotech, Rgenix, and Xencor. C.M. has received consulting fees from Amgen, Astellas Pharma, AstraZeneca, Bayer, BeiGene, Blueprint Medicines, Bristol Myers Squibb, Celgene, Debiopharm Group, Faron Pharmaceuticals, Genentech/Roche, Innate Pharma, Ipsen, Janssen, Lilly, MSD, Novartis, Orion, Pfizer, PharmaMar, Sanofi, and Taiho Pharmaceutical. D.A.R. has received financial support for advisory input from Agios, AnHeart Therapeutics, Avita Biomedical Inc., Blue Rock Therapeutics, Bristol Myers Squibb, Boston Biomedical, CureVac AG, Del Mar Pharma, DNAtrix, Hoffman&#x02010;LaRoche Ltd., Imvax, Janssen, Kiyatec, Medicenna Therapeutics, Neuvogen, Novartis, Novocure, Pyramid, Sumitomo Dainippon Pharma, Vivacitas Oncology Inc., and Y&#x02010;mabs Therapeutics. Y.L. has received consulting fees from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Immunomedics, Janssen (and institutional), MSD Oncology (and institutional), Loxo/Lilly, Pfizer/EMD Serono, Roche, and Taiho Pharmaceutical; has been reimbursed for travel, accommodations, or expenses from Astellas, AstraZeneca, Janssen Oncology, MSD Oncology, and Roche; and has received institutional research funding from Astellas Pharma, AstraZeneca, Basilea, Bristol Myers Squibb, Exelixis, Gilead Sciences, Incyte, Janssen Oncology, Merck KGaA, MSD Oncology, Nektar, Pfizer, Roche, Sanofi, and Taiho Pharmaceutical. M.S. has received consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen Oncology, Merck Serono, Novartis, Roche, Sanofi, and Takeda; honoraria from Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen&#x02010;Cilag, and Novartis; institutional research funding from AstraZeneca and Bristol Myers Squibb; and has institutional patents, royalties, or other intellectual property for a highly sensitive method for mutation detection by PCR.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="cam470546-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="CAM4-14-e70546-s001.docx"/></supplementary-material></sec></body><back><ack id="cam470546-sec-0020"><title>Acknowledgments</title><p>This study was funded by Janssen Research &#x00026; Development, LLC. Writing assistance was provided by Ira Mills, PhD, of Parexel, and was funded by Janssen Global Services, LLC.</p></ack><sec sec-type="data-availability" id="cam470546-sec-0024"><title>Data Availability Statement</title><p>Janssen Pharmaceutical Companies of Johnson &#x00026; Johnson's data sharing policy is available at <ext-link xlink:href="https://www.janssen.com/clinical-trials/transparency" ext-link-type="uri" specific-use="software is-supplemented-by">https://www.janssen.com/clinical&#x02010;trials/transparency</ext-link>. As noted on this site, requests for study data access can be submitted through the Yale Open Data Access (YODA) project site at <ext-link xlink:href="http://yoda.yale.edu" ext-link-type="uri" specific-use="software is-supplemented-by">http://yoda.yale.edu</ext-link>.</p></sec><ref-list content-type="cited-references" id="cam470546-bibl-0001"><title>References</title><ref id="cam470546-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam470546-cit-0001">
<string-name>
<given-names>E. M.</given-names>
<surname>Haugsten</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Wiedlocha</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Olsnes</surname>
</string-name>, and <string-name>
<given-names>J.</given-names>
<surname>Wesche</surname>
</string-name>, &#x0201c;<article-title>Roles of Fibroblast Growth Factor Receptors in Carcinogenesis</article-title>,&#x0201d; <source>Molecular Cancer Research</source>
<volume>8</volume>, no. <issue>11</issue> (<year>2010</year>): <fpage>1439</fpage>&#x02013;<lpage>1452</lpage>, <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-10-0168</pub-id>.<pub-id pub-id-type="pmid">21047773</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam470546-cit-0002">
<string-name>
<given-names>R.</given-names>
<surname>Dienstmann</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Rodon</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Prat</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Genomic Aberrations in the FGFR Pathway: Opportunities for Targeted Therapies in Solid Tumors</article-title>,&#x0201d; <source>Annals of Oncology</source>
<volume>25</volume>, no. <issue>3</issue> (<year>2014</year>): <fpage>552</fpage>&#x02013;<lpage>563</lpage>, <pub-id pub-id-type="doi">10.1093/annonc/mdt419</pub-id>.<pub-id pub-id-type="pmid">24265351</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam470546-cit-0003">
<string-name>
<given-names>M.</given-names>
<surname>Katoh</surname>
</string-name>, &#x0201c;<article-title>Fibroblast Growth Factor Receptors as Treatment Targets in Clinical Oncology</article-title>,&#x0201d; <source>Nature Reviews. Clinical Oncology</source>
<volume>16</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>105</fpage>&#x02013;<lpage>122</lpage>, <pub-id pub-id-type="doi">10.1038/s41571-018-0115-y</pub-id>.</mixed-citation></ref><ref id="cam470546-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam470546-cit-0004">
<string-name>
<given-names>Y.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Su</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yang</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>FGF/FGFR Signaling in Health and Disease</article-title>,&#x0201d; <source>Signal Transduction and Targeted Therapy</source>
<volume>5</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>181</fpage>, <pub-id pub-id-type="doi">10.1038/s41392-020-00222-7</pub-id>.<pub-id pub-id-type="pmid">32879300</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam470546-cit-0005">
<collab collab-type="authors">AACR Project GENIE Consortium</collab>
, &#x0201c;<article-title>AACR Project GENIE: Powering Precision Medicine Through an International Consortium</article-title>,&#x0201d; <source>Cancer Discovery</source>
<volume>7</volume>, no. <issue>8</issue> (<year>2017</year>): <fpage>818</fpage>&#x02013;<lpage>831</lpage>, <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0151</pub-id>.<pub-id pub-id-type="pmid">28572459</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam470546-cit-0006">
<string-name>
<given-names>F. J.</given-names>
<surname>Xie</surname>
</string-name>, <string-name>
<given-names>H. Y.</given-names>
<surname>Lu</surname>
</string-name>, <string-name>
<given-names>Q. Q.</given-names>
<surname>Zheng</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Clinical Pathological Characteristics and Prognosis of FGFR1 Gene Amplification in Non&#x02010;small&#x02010;Cell Lung Cancer: A Meta&#x02010;Analysis</article-title>,&#x0201d; <source>Oncotargets and Therapy</source>
<volume>9</volume> (<year>2016</year>): <fpage>171</fpage>&#x02013;<lpage>181</lpage>, <pub-id pub-id-type="doi">10.2147/OTT.S91848</pub-id>.<pub-id pub-id-type="pmid">26793001</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam470546-cit-0007">
<string-name>
<given-names>L.</given-names>
<surname>Pacini</surname>
</string-name>, <string-name>
<given-names>A. D.</given-names>
<surname>Jenks</surname>
</string-name>, <string-name>
<given-names>N. C.</given-names>
<surname>Lima</surname>
</string-name>, and <string-name>
<given-names>P. H.</given-names>
<surname>Huang</surname>
</string-name>, &#x0201c;<article-title>Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer</article-title>,&#x0201d; <source>Cells</source>
<volume>10</volume>, no. <issue>5</issue> (<year>2021</year>), <pub-id pub-id-type="doi">10.3390/cells10051154</pub-id>.</mixed-citation></ref><ref id="cam470546-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam470546-cit-0008">
<string-name>
<given-names>M. J.</given-names>
<surname>Borad</surname>
</string-name>, <string-name>
<given-names>M. D.</given-names>
<surname>Champion</surname>
</string-name>, <string-name>
<given-names>J. B.</given-names>
<surname>Egan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma</article-title>,&#x0201d; <source>PLoS Genetics</source>
<volume>10</volume>, no. <issue>2</issue> (<year>2014</year>): <elocation-id>e1004135</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pgen.1004135</pub-id>.<pub-id pub-id-type="pmid">24550739</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam470546-cit-0009">
<string-name>
<given-names>Y.</given-names>
<surname>Arai</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Totoki</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Hosoda</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma</article-title>,&#x0201d; <source>Hepatology</source>
<volume>59</volume>, no. <issue>4</issue> (<year>2014</year>): <fpage>1427</fpage>&#x02013;<lpage>1434</lpage>, <pub-id pub-id-type="doi">10.1002/hep.26890</pub-id>.<pub-id pub-id-type="pmid">24122810</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam470546-cit-0010">
<string-name>
<given-names>D.</given-names>
<surname>Sia</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Losic</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Moeini</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Massive Parallel Sequencing Uncovers Actionable FGFR2&#x02010;PPHLN1 Fusion and ARAF Mutations in Intrahepatic Cholangiocarcinoma</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>6</volume> (<year>2015</year>): <fpage>6087</fpage>, <pub-id pub-id-type="doi">10.1038/ncomms7087</pub-id>.</mixed-citation></ref><ref id="cam470546-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam470546-cit-0011">
<string-name>
<given-names>S.</given-names>
<surname>Pant</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Schuler</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Iyer</surname>
</string-name>, et&#x000a0;al., on behalf of the <collab collab-type="authors">RAGNAR Investigators</collab>
, &#x0201c;<article-title>Erdafitinib in Patients With Advanced Solid Tumours With FGFR Alterations (RAGNAR): An International, Single&#x02010;Arm, Phase 2 Study</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>24</volume>, no. <issue>8</issue> (<year>2023</year>): <fpage>925</fpage>&#x02013;<lpage>935</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(23)00275-9</pub-id>.<pub-id pub-id-type="pmid">37541273</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam470546-cit-0012">
<string-name>
<given-names>H. S.</given-names>
<surname>Friedman</surname>
</string-name>, <string-name>
<given-names>M. D.</given-names>
<surname>Prados</surname>
</string-name>, <string-name>
<given-names>P. Y.</given-names>
<surname>Wen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma</article-title>,&#x0201d; <source>Journal of Clinical Oncology</source>
<volume>27</volume>, no. <issue>28</issue> (<year>2009</year>): <fpage>4733</fpage>&#x02013;<lpage>4740</lpage>, <pub-id pub-id-type="doi">10.1200/JCO.2008.19.8721</pub-id>.<pub-id pub-id-type="pmid">19720927</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam470546-cit-0013">
<string-name>
<given-names>J.</given-names>
<surname>Valle</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wasan</surname>
</string-name>, <string-name>
<given-names>D. H.</given-names>
<surname>Palmer</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cisplatin Plus Gemcitabine Versus Gemcitabine for Biliary Tract Cancer</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>362</volume>, no. <issue>14</issue> (<year>2010</year>): <fpage>1273</fpage>&#x02013;<lpage>1281</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa0908721</pub-id>.<pub-id pub-id-type="pmid">20375404</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam470546-cit-0014">
<string-name>
<given-names>E. J.</given-names>
<surname>Walker</surname>
</string-name> and <string-name>
<given-names>A. H.</given-names>
<surname>Ko</surname>
</string-name>, &#x0201c;<article-title>Beyond First&#x02010;Line Chemotherapy for Advanced Pancreatic Cancer: An Expanding Array of Therapeutic Options?</article-title>,&#x0201d; <source>World Journal of Gastroenterology</source>
<volume>20</volume>, no. <issue>9</issue> (<year>2014</year>): <fpage>2224</fpage>&#x02013;<lpage>2236</lpage>, <pub-id pub-id-type="doi">10.3748/wjg.v20.i9.2224</pub-id>.<pub-id pub-id-type="pmid">24605022</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0015"><label>15</label><mixed-citation publication-type="book" id="cam470546-cit-0015">
<collab collab-type="authors">International Association for the Study of Lung Cancer</collab>
, <source>IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer</source> (<publisher-loc>Denver, CO, USA</publisher-loc>: <collab collab-type="authors">International Association for the Study of Lung Cancer</collab>
, <year>2024</year>), <ext-link xlink:href="https://www.iaslc.org/iaslc-atlas-molecular-testing-targeted-therapy-lung-cancer" ext-link-type="uri">https://www.iaslc.org/iaslc&#x02010;atlas&#x02010;molecular&#x02010;testing&#x02010;targeted&#x02010;therapy&#x02010;lung&#x02010;cancer</ext-link>.</mixed-citation></ref><ref id="cam470546-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam470546-cit-0016">
<string-name>
<given-names>J.</given-names>
<surname>Malhotra</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Ryan</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Patel</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Clinical Outcomes and Immune Phenotypes Associated With STK11 Co&#x02010;Occurring Mutations in Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>Journal of Thoracic Disease</source>
<volume>14</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>1772</fpage>&#x02013;<lpage>1783</lpage>, <pub-id pub-id-type="doi">10.21037/jtd-21-1377</pub-id>.<pub-id pub-id-type="pmid">35813711</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam470546-cit-0017">
<string-name>
<given-names>P.</given-names>
<surname>Rosellini</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Amintas</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Caumont</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Clinical Impact of STK11 Mutation in Advanced&#x02010;Stage Non&#x02010;Small Cell Lung Cancer</article-title>,&#x0201d; <source>European Journal of Cancer</source>
<volume>172</volume> (<year>2022</year>): <fpage>85</fpage>&#x02013;<lpage>95</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejca.2022.05.026</pub-id>.<pub-id pub-id-type="pmid">35759814</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam470546-cit-0018">
<string-name>
<given-names>M. S.</given-names>
<surname>Alam</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Sultana</surname>
</string-name>, <string-name>
<given-names>M. S.</given-names>
<surname>Reza</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Amanullah</surname>
</string-name>, <string-name>
<given-names>S. R.</given-names>
<surname>Kabir</surname>
</string-name>, and <string-name>
<given-names>M. N. H.</given-names>
<surname>Mollah</surname>
</string-name>, &#x0201c;<article-title>Integrated Bioinformatics and Statistical Approaches to Explore Molecular Biomarkers for Breast Cancer Diagnosis, Prognosis and Therapies</article-title>,&#x0201d; <source>PLoS One</source>
<volume>17</volume>, no. <issue>5</issue> (<year>2022</year>): <elocation-id>e0268967</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0268967</pub-id>.<pub-id pub-id-type="pmid">35617355</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam470546-cit-0019">
<string-name>
<given-names>M.</given-names>
<surname>Rakhshaninejad</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Fathian</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Shirkoohi</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Barzinpour</surname>
</string-name>, and <string-name>
<given-names>A. H.</given-names>
<surname>Gandomi</surname>
</string-name>, &#x0201c;<article-title>Refining Breast Cancer Biomarker Discovery and Drug Targeting Through an Advanced Data&#x02010;Driven Approach</article-title>,&#x0201d; <source>BMC Bioinformatics</source>
<volume>25</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>33</fpage>, <pub-id pub-id-type="doi">10.1186/s12859-024-05657-1</pub-id>.<pub-id pub-id-type="pmid">38253993</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam470546-cit-0020">
<string-name>
<given-names>H.</given-names>
<surname>Hozhabri</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Moghaddam</surname>
</string-name>, <string-name>
<given-names>M. M.</given-names>
<surname>Moghaddam</surname>
</string-name>, and <string-name>
<given-names>A.</given-names>
<surname>Mohammadian</surname>
</string-name>, &#x0201c;<article-title>A Comprehensive Bioinformatics Analysis to Identify Potential Prognostic Biomarkers Among CC and CXC Chemokines in Breast Cancer</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>12</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>10374</fpage>, <pub-id pub-id-type="doi">10.1038/s41598-022-14610-2</pub-id>.<pub-id pub-id-type="pmid">35725915</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0021"><label>21</label><mixed-citation publication-type="book" id="cam470546-cit-0021">
<collab collab-type="authors">LYTGOBI&#x000ae; (futibatinib) [prescribing information]</collab>
, <source>Taiho Pharmaceutical co., Ltd</source> (<publisher-loc>Japan</publisher-loc>, <year>2022</year>).</mixed-citation></ref><ref id="cam470546-bib-0022"><label>22</label><mixed-citation publication-type="book" id="cam470546-cit-0022">
<collab collab-type="authors">PEMAZYRE&#x000ae; (pemigatinib)</collab>
[prescribing information], <source>Incyte Corporation</source> (<publisher-loc>Wilmington, DE</publisher-loc>, <year>2023</year>).</mixed-citation></ref><ref id="cam470546-bib-0023"><label>23</label><mixed-citation publication-type="book" id="cam470546-cit-0023">
<string-name>
<given-names>U. S.</given-names>
<surname>Food</surname>
</string-name> and <string-name>
<given-names>Drug</given-names>
<surname>Administration</surname>
</string-name>, <source>FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma</source>, (<year>2022</year>), Accessed September 29, 2023. <ext-link xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources&#x02010;information&#x02010;approved&#x02010;drugs/fda&#x02010;grants&#x02010;accelerated&#x02010;approval&#x02010;infigratinib&#x02010;metastatic&#x02010;cholangiocarcinoma</ext-link>.</mixed-citation></ref><ref id="cam470546-bib-0024"><label>24</label><mixed-citation publication-type="book" id="cam470546-cit-0024">
<collab collab-type="authors">BALVERSA&#x000ae; (erdafitinib)</collab>
[prescribing information], <source>Janssen Pharmaceutical Companies</source> (<publisher-loc>Horsham, PA</publisher-loc>, <year>2024</year>).</mixed-citation></ref><ref id="cam470546-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam470546-cit-0025">
<string-name>
<given-names>Y.</given-names>
<surname>Loriot</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Matsubara</surname>
</string-name>, <string-name>
<given-names>S. H.</given-names>
<surname>Park</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>389</volume>, no. <issue>21</issue> (<year>2023</year>): <fpage>1961</fpage>&#x02013;<lpage>1971</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa2308849</pub-id>.<pub-id pub-id-type="pmid">37870920</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam470546-cit-0026">
<string-name>
<given-names>Y.</given-names>
<surname>Loriot</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Necchi</surname>
</string-name>, <string-name>
<given-names>S. H.</given-names>
<surname>Park</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma</article-title>,&#x0201d; <source>New England Journal of Medicine</source>
<volume>381</volume>, no. <issue>4</issue> (<year>2019</year>): <fpage>338</fpage>&#x02013;<lpage>348</lpage>, <pub-id pub-id-type="doi">10.1056/NEJMoa1817323</pub-id>.<pub-id pub-id-type="pmid">31340094</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam470546-cit-0027">
<string-name>
<given-names>A. O.</given-names>
<surname>Siefker&#x02010;Radtke</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Necchi</surname>
</string-name>, <string-name>
<given-names>S. H.</given-names>
<surname>Park</surname>
</string-name>, et&#x000a0;al., on behalf of the <collab collab-type="authors">BLC2001 Study Group</collab>
, &#x0201c;<article-title>Efficacy and Safety of Erdafitinib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: Long&#x02010;Term Follow&#x02010;Up of a Phase 2 Study</article-title>,&#x0201d; <source>Lancet Oncology</source>
<volume>23</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>248</fpage>&#x02013;<lpage>258</lpage>, <pub-id pub-id-type="doi">10.1016/S1470-2045(21)00660-4</pub-id>.<pub-id pub-id-type="pmid">35030333</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0028"><label>28</label><mixed-citation publication-type="book" id="cam470546-cit-0028">
<collab collab-type="authors">Clinicaltrials.gov</collab>
, <source>A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)</source> Accessed December 23, 2022. <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04083976" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/NCT04083976</ext-link>.</mixed-citation></ref><ref id="cam470546-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam470546-cit-0029">
<string-name>
<given-names>G.</given-names>
<surname>Singal</surname>
</string-name>, <string-name>
<given-names>P. G.</given-names>
<surname>Miller</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Agarwala</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non&#x02010;small Cell Lung Cancer Using a Clinicogenomic Database</article-title>,&#x0201d; <source>JAMA The Journal of the American Medical Association</source>
<volume>321</volume>, no. <issue>14</issue> (<year>2019</year>): <fpage>1391</fpage>&#x02013;<lpage>1399</lpage>, <pub-id pub-id-type="doi">10.1001/jama.2019.3241</pub-id>.<pub-id pub-id-type="pmid">30964529</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cam470546-cit-0030">
<string-name>
<given-names>G. M.</given-names>
<surname>Frampton</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Fichtenholtz</surname>
</string-name>, <string-name>
<given-names>G. A.</given-names>
<surname>Otto</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Development and Validation of a Clinical Cancer Genomic Profiling Test Based on Massively Parallel DNA Sequencing</article-title>,&#x0201d; <source>Nature Biotechnology</source>
<volume>31</volume>, no. <issue>11</issue> (<year>2013</year>): <fpage>1023</fpage>&#x02013;<lpage>1031</lpage>, <pub-id pub-id-type="doi">10.1038/nbt.2696</pub-id>.</mixed-citation></ref><ref id="cam470546-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cam470546-cit-0031">
<string-name>
<given-names>F.</given-names>
<surname>Facchinetti</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Hollebecque</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Braye</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Resistance to Selective FGFR Inhibitors in FGFR&#x02010;Driven Urothelial Cancer</article-title>,&#x0201d; <source>Cancer Discovery</source>
<volume>13</volume>, no. <issue>9</issue> (<year>2023</year>): <fpage>1998</fpage>&#x02013;<lpage>2011</lpage>, <pub-id pub-id-type="doi">10.1158/2159-8290.CD-22-1441</pub-id>.<pub-id pub-id-type="pmid">37377403</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cam470546-cit-0032">
<string-name>
<given-names>K.</given-names>
<surname>Yadav</surname>
</string-name> and <string-name>
<given-names>R. J.</given-names>
<surname>Lewis</surname>
</string-name>, &#x0201c;<article-title>Immortal Time Bias in Observational Studies</article-title>,&#x0201d; <source>JAMA The Journal of the American Medical Association</source>
<volume>325</volume>, no. <issue>7</issue> (<year>2021</year>): <fpage>686</fpage>&#x02013;<lpage>687</lpage>, <pub-id pub-id-type="doi">10.1001/jama.2020.9151</pub-id>.<pub-id pub-id-type="pmid">33591334</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cam470546-cit-0033">
<string-name>
<given-names>E. A.</given-names>
<surname>Stuart</surname>
</string-name>, &#x0201c;<article-title>Matching Methods for Causal Inference: A Review and a Look Forward</article-title>,&#x0201d; <source>Statistical Science</source>
<volume>25</volume>, no. <issue>1</issue> (<year>2010</year>): <fpage>1</fpage>&#x02013;<lpage>21</lpage>, <pub-id pub-id-type="doi">10.1214/09-STS313</pub-id>.<pub-id pub-id-type="pmid">20871802</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cam470546-cit-0034">
<string-name>
<given-names>Z.</given-names>
<surname>Zhang</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Lonjon</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zhu</surname>
</string-name>, written on behalf of <collab collab-type="authors">AME Big&#x02010;Data Clinical Trial Collaborative Group</collab>
, &#x0201c;<article-title>Balance Diagnostics After Propensity Score Matching</article-title>,&#x0201d; <source>Annals of Translational Medicine</source>
<volume>7</volume>, no. <issue>1</issue> (<year>2019</year>), <pub-id pub-id-type="doi">10.21037/atm.2018.12.10</pub-id>.</mixed-citation></ref><ref id="cam470546-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cam470546-cit-0035">
<string-name>
<given-names>A.</given-names>
<surname>Jain</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Borad</surname>
</string-name>, <string-name>
<given-names>R. K.</given-names>
<surname>Kelley</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype</article-title>,&#x0201d; <source>JCO Precision Oncology</source>
<volume>2</volume> (<year>2018</year>): <fpage>1</fpage>&#x02013;<lpage>12</lpage>, <pub-id pub-id-type="doi">10.1200/PO.17.00080</pub-id>.</mixed-citation></ref><ref id="cam470546-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cam470546-cit-0036">
<string-name>
<given-names>M.</given-names>
<surname>Rizzato</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Brignola</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Munari</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Prognostic Impact of FGFR2/3 Alterations in Patients With Biliary Tract Cancers Receiving Systemic Chemotherapy: The BITCOIN Study</article-title>,&#x0201d; <source>European Journal of Cancer</source>
<volume>166</volume> (<year>2022</year>): <fpage>165</fpage>&#x02013;<lpage>175</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejca.2022.02.013</pub-id>.<pub-id pub-id-type="pmid">35303508</pub-id>
</mixed-citation></ref><ref id="cam470546-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cam470546-cit-0037">
<string-name>
<given-names>R.</given-names>
<surname>Mayr</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Eckstein</surname>
</string-name>, <string-name>
<given-names>R. M.</given-names>
<surname>Wirtz</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High&#x02010;Grade Non&#x02010;muscle&#x02010;Invasive Bladder Cancer Treated With and Without Bacillus Calmette&#x02010;Guerin Immunotherapy</article-title>,&#x0201d; <source>European Urology</source>
<volume>81</volume>, no. <issue>6</issue> (<year>2022</year>): <fpage>606</fpage>&#x02013;<lpage>614</lpage>, <pub-id pub-id-type="doi">10.1016/j.eururo.2022.02.028</pub-id>.<pub-id pub-id-type="pmid">35351346</pub-id>
</mixed-citation></ref></ref-list></back></article>